Article Versions Notes

Cardama GA, Maggio J, Valdez Capuccino L, Gonzalez N, Matiller V, Ortega HH, Perez GR, Demarco IA, Spitzer E, Gomez DE, et al. Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models. Cancers. 2022; 14(19):4810. https://doi.org/10.3390/cancers14194810

Cardama, Georgina A., Julian Maggio, Lucas Valdez Capuccino, Nazareno Gonzalez, Valentina Matiller, Hugo H. Ortega, German R. Perez, Ignacio A. Demarco, Eduardo Spitzer, Daniel E. Gomez, and et al. 2022. "Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models" Cancers 14, no. 19: 4810. https://doi.org/10.3390/cancers14194810

Cardama, G. A., Maggio, J., Valdez Capuccino, L., Gonzalez, N., Matiller, V., Ortega, H. H., Perez, G. R., Demarco, I. A., Spitzer, E., Gomez, D. E., Lorenzano Menna, P., & Alonso, D. F. (2022). Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models. Cancers, 14(19), 4810. https://doi.org/10.3390/cancers14194810